Eucalyptus is an Australian telemedicine platform that connects patients with healthcare practitioners, providing asynchronous consultations to diagnose and provide treatments. The company operates a direct-to-consumer business model, offering a range of virtual care services via five healthcare-related portals that cover men’s health, fertility care, sexual health, skincare, and menopause. Since its launch in 2019, Eucalyptus has provided 500,000 consultations to date and claims to be the largest vertically integrated telehealth platform in Australia.
Patients begin by filling out an online questionnaire before being contacted by a licensed healthcare practitioner for a text-based consultation. Prescriptions are fulfilled through third-party pharmacies and are delivered by mail. It also operates an online store, where users can purchase non-prescription products. These services are available to individuals for a monthly subscription fee.
In January 2022, it raised AUD 60 million (USD 42 million) in a Series C funding round led by Bond, with plans to scale up its staff of 200 as well as enter into the international markets, initially starting with the UK. The proceeds will also be used to enhance its platform.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.